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ABSTRACT 
 
SQUAMOUS CELL CARCINOMA RESPOSNE TO CISPLATIN EXPSOURE 
Khanh V. Luong, D.D.S 
University of Nebraska, 2015 
Advisor: Aimin Peng, Ph.D. 
 Purpose: This thesis attempted to quantitatively analyze the individual cell 
fate choice in resistant head and neck UM-SCC38 cells exposed to cisplatin 
using the most current techniques available.  
 Methods: UM-SCC-38 cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS).  They were 
treated with cisplatin and ATM/ATR inhibitors of known dosages. Using live cell 
imaging, one hundred cells were tracked in each experiment and their behaviors 
were analyzed and entered into Microsoft Excel Spreadsheet to generate cell 
profile graphs. HaCaT cells, non-tumorigenic keratinocyte cell line, were also 
analyzed using live cell imaging and their cell fate profiles generated to better 
understand the resistance of SCC-38 to cisplatin. 
 Results: Our study revealed a highly heterogeneous pattern of cell fate 
choices in SCC-38, in comparison to that of the control, HaCaT, cells.  In both 
SCC-38 and HaCaT cell lines, the majority of cell death occurred in the 
immediate interphase without mitotic entry, whereas significant portions of SCC-
38 cells survived the treatment via either checkpoint arrest or checkpoint 
slippage. Cells that exhibited checkpoint slippage were primarily treated or 
vii 
 
exposed to cisplatin at late-S and G2 phases. Our study also revealed cells in M-
phase were hypersensitive to cisplatin. Moreover, although the cisplatin resistant 
progression of mitosis exhibited no delay in general, greatly prolonged mitosis 
correlated with the induction of cell death in mitosis. This finding suggested a 
combinatorial treatment using cisplatin and an agent that blocks mitotic exit, Mg-
132. Consistently, we showed a strong synergy between cisplatin and the 
proteasome inhibitor Mg-132. Finally, targeting DNA damage checkpoint using 
ATR inhibitor effectively sensitized SCC-38 to cisplatin treatment. To our 
surprise, targeting checkpoint eliminated both checkpoint arrest and checkpoint 
slippage, and augmented the induction of cell death in interphase without mitotic 
entry.  
 Conclusion: The diverse cell fate choices of SCC-38 and HaCaT cells 
were confirmed using live cell imaging. Our results showed the majority of cell 
death occurred in interphase without mitotic entry and a significantly smaller 
portion of SCC-38 cells died after the cisplatin treatment when compared to 
HaCaT. On the other hand, analysis of the surviving SCC-38 cells revealed the 
co-existence of checkpoint arrest and checkpoint slippage.  However, caffeine 
was shown to abolish these surviving mechanisms in cisplatin treated cells.  
Moreover, our combination therapy of cisplatin plus MG-132 showed strong 
synergistic effect on SCC-38 cell death. Overall, our study revealed new insights 
into chemoresistance and suggested combinatorial strategies that potentially 
overcome cancer resistance.   
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CHAPTER 1: INTRODUCTION 
 
Squamous cell carcinoma (SCC) of the head and neck is the sixth most 
common malignancy in the world today (Lingen et al 2010). The etiology is multi-
factorial and site-specific. For instance, oral cavity SCC has long been 
associated with tobacco and alcohol abuse.  Despite numerous advances in 
early cancer detection, prevention, and treatment, the overall 5-year survival 
remains modest at best (Lingen et al 2010).  
At the molecular level, cancer is characterized as genetic alterations to 
individual cells, leading to cellular functions such as resistance to cell death, 
increased cell proliferation, and the ability to invade and metastasize (Teng 
2015). To combat such tumorigenic cellular behaviors, genotoxic agents are 
designed to induce apoptosis and other cell death pathways by causing DNA 
damage (Jackson, 2009). Cancer cells can be particularly vulnerable to DNA 
damage as they actively undergo DNA replication and cell proliferation. However, 
the therapeutic benefit of chemotherapy is limited in many clinical cases due to 
intrinsic or acquired resistance of tumor cells to DNA damage. Thus, it has been 
suggested that targeting the cellular DNA damage response (DDR) may offer a 
valuable tool to improve the therapeutic window and effectiveness of 
chemotherapy (Bolderson et al 2009, Al-Ejeh et al 2010). 
Among the most successful and commonly used chemotherapeutic drugs 
are cisplatin (cis-diamminedichloroplatinum) and other platinum-based drugs. 
Cisplatin was first approved by the FDA in 1978 for the treatment of testicular 
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and bladder cancer (Galluzzi et al 2011). Over the past decades, cisplatin and its 
variants have been prescribed for an estimated 10 to 20 percent of all cancer 
patients. The use of cisplatin in the treatment of testicular cancer improved the 
cure rate from 10% to 80%. Today, cisplatin is broadly used for a wide range of 
other solid tumors, including those of lung, breast, ovarian, head and neck, etc. 
However, the efficacy of cisplatin in these other solid tumors appears less 
satisfactory, as many tumors either exhibit intrinsic resistance to cisplatin or 
relapse despite initial response (Galluzzi et al 2011, Caponigro et al 2006). 
Like other genotoxic drugs or radiation, cisplatin exerts cytotoxicity by 
inducing DNA damage. Specifically, cisplatin binds DNA and cause DNA inter- or 
intra-strand crosslinking, a form of DNA damage that blocks DNA replication and 
transcription (Galluzzi et al 2011, Caponigro et al 2006). The occurrence of DNA 
damage quickly activates the DDR, a conserved mechanism evolved in 
eukaryotic cells to govern genomic integrity. The DDR encompasses various 
lesion specific DNA repair pathways, and a sophisticated signaling network that 
activates the cell cycle checkpoint and cell death (Zhou  2000, Jackson 2009). At 
the center of the molecular pathway of the DDR are the phosphoinositide 3-
kinase-related kinases (PIKK) ATM and ATR. Activation of ATM and ATR by 
DNA damage in turn results in phosphorylation of dozens of physiological 
substrates that control various pathways including DNA repair, checkpoint 
control, and apoptosis (Shiloh 2003). For example, ATM and ATR activate the 
checkpoint kinases Chk1 and Chk2, which phosphorylate and inactivate Cdc25, 
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an activator of cyclin-dependent kinases (Cdks), and thereby preventing Cdk 
activation and cell cycle progression (Sancar et al 2004).  
The ultimate result of the DDR can be either cell survival or cell death, and 
the choice between them may essentially dictate the outcome of cancer therapy. 
In fact, several distinct cell fate choices should be considered. First, cell death 
can be induced as the desired outcome that leads to therapeutic benefit. 
Alternatively, the cell may cease proliferation via sustained activation of the DNA 
damage checkpoint, a state described as senescence. Although this cell fate 
choice halts the growth of tumor cells, these cells may re-enter the cell cycle 
progression after acquiring additional changes. Finally, and perhaps of the worst 
possibility, cancer cells may continue cell proliferation despite the treatment. 
In this study we use automated time-lapse microscopy to quantitate the profile of 
cell fate determination in resistant cancer cells treated with cisplatin. Our study 
revealed heterogeneous and complex pattern of cell fate determination in these 
cancer cells. The results suggested the potential cause of cell protection via both 
checkpoint activation and checkpoint slippage. More interestingly, our analyses 
revealed new insights into how targeting mitotic exit and the DNA damage 
checkpoint can alter the pattern of cell fate choices and enhance the treatment 
efficacy.  
  
4 
 
CHAPTER 2: LITERATURE REVIEW 
 
2.1 DNA Damage Response (DDR) Pathways 
 
Each cell in the human body is under constant threat to DNA lesions from 
both the endogenous and environment agents. The most pervasive 
environmental DNA-damaging agent is UV light from the sun, which can induce 
~100,000 lesions per exposed cell per hour (Jackson 2009). Other common 
forms of environmental DNA-damaging agent are ionizing radiation and tobacco 
products. Ionizing radiation can cause double-strand breaks (DSBs), while 
tobacco products can trigger various cancers, most notably those of the lung and 
oral cavity (Jackson 2009).  Metabolic products such as reactive oxygen species 
also present challenge to the genomic stability. While the prime objective of each 
cell is to deliver its genetic material, intact and unchanged, to the next 
generation, the DNA damage incurred by each cell must be repaired to prevent 
incorrect transmission of the genetic material. To counter both the endogenous 
and environmental threats, cells have evolved an intricate series of mechanisms 
to first, detect DNA damage, second, to accumulate DNA repair factors and third, 
physically repair the lesion (Zhou 2000). Collectively, these mechanisms are 
known as the DNA damage response (DDR). In general, DDR can be divided 
into distinct pathways based on the type of DNA lesion they process. For 
example, simple DNA changes, such as oxidative lesions and single-strand 
breaks (SSBs), are repaired through a mechanism called base excision repair 
(BER); while major mechanisms that cope with double-strand breaks (DSBs) are 
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homologous recombination and non-homologous end joining (NHEJ) (Lord 
2012). The ultimate results of the DDR can either be cell survival or control cell 
death.  If the cell successfully repairs DNA damage, it would turn off the DDR 
and return to normal cell proliferation; likely wise, if the damage cannot be 
removed, chronic DDR signaling triggers cell death by apoptosis. However, if the 
DNA repair mechanism fails, three possible fates are ensured: (1) senescence, 
(2) apoptosis, and worst of all (3) tumor formation. 
2.2 Cisplatin and Its Molecular Mechanisms 
 
Platinum-based drugs are best known for treatment of various solid 
tumors, including testicular, ovarian, head and neck, colorectal, bladder and lung 
cancers (Galluzzi et al 2011). Cis-diammineplatinum (II) dichloride (best known 
as cisplatin) was first approved by the FDA in 1978 for the treatment of testicular 
and bladder cancer (Galluzzi et al 2011). Today, cisplatin is a largely employed 
platinum-based compound for the treatment of wide spectrum of solid 
neoplasms, such as testicular, bladder, ovarian, colorectal, lung and head and 
neck cancers (Toulany et al 2014).  Despite positive initial responses, many 
cancer patients eventually develop chemoresistance to cisplatin-based therapies, 
leading to relapse and therapeutic failure. High incidence of chemoresistance is 
cited as the main clinical limitation to the usefulness of cisplatin (Toulany 2014). 
Therefore, circumventing cisplatin resistance is a critical goal for anticancer 
therapy and considerable efforts have been undertaken to solve this problem 
throughout the past decades.  
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 The detailed description of the molecular mechanism of cisplatin can be 
found elsewhere (Sanderson et al 1996, Siddik 2003). In general, cisplatin exerts 
its anticancer effects via a complex signaling pathway.  Upon cellular absorption 
and processing, cisplatin must be intracellularly activated by a series of reactions 
that consist of substituting one or both cis-chloro groups with water molecules 
(Sanderson et al 1996). Equated cisplatin is active and can cause significant 
damages to both the cytoplasm and nucleus.  In the nucleus, cisplatin avidly 
binds to DNA and causes DNA strand cross-linking. Such distortions in the DNA 
can be recognized by multiple repair pathways (Siddik 2003). The major 
signaling network that senses DNA lesion is the DNA damage response (DDR) 
as discussed above.  
2.3 DNA Damage Checkpoints 
 
Cell cycle checkpoints are control mechanisms composed of signaling 
pathways that control the ability of cells to arrest the cell cycle in response to 
DNA damage, allowing time for repair. Moreover, it controls the activation of DNA 
repair pathways and the movement of DNA repair proteins to sites of DNA 
damage (Zhou 2000).  
The recognition of DNA lesions involves the sequential activation of DNA 
damage sensors, transducers, and effectors. The ataxia telangiectasia mutated 
(ATM) and RAD3-related protein (ATR) are important sensors of the DNA 
damage and have been shown to participate in cisplatin-induced DNA damage. 
Activation of ATM and ATR leads to downstream phosphorylation of various 
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physiologic substrates (Wang et al 2012). For instance, ATM and ATR activate 
checkpoint kinase 1 (Chk1, the most prominent substrate and effector of ATR) 
and checkpoint kinase 2, respectively.  Chk1 and Chk2 then phosphorylate and 
inactivate Cdc25, an activator of cyclin-dependent kinases (Cdks), and thereby 
preventing Cdk activation and cell cycle progression. In addition, activated ATM 
and ATR also phosphorylate H2AX at the site of DNA damage, which recruits a 
number of DDR factors to facilitate DNA repair and checkpoint signaling (Wang 
et al 2012).  
Despite similarity in functions, ATM and ATR are activated through 
different mechanisms. Mre11-Rad50-Nbs1 complex is the primary sensor of 
double strand breaks (DSBs). It migrates rapidly to the sites of DMA damage to 
form nuclear foci and facilitates the recruitment of ATM (Hurley and Bunz 2007). 
ATR, on the other hand, functions as a sensor for single strand DNA (ssDNA) 
damage (Hurley and Bunz 2007).  
2.4 Caffeine and Its Molecular Mechanism 
 
 Caffeine is a popular central nervous system (CNS) stimulant and 
commonly used as a stimulant to prevent sleepiness. It is found in coffee, tea, 
cola nuts, and cocoa. For many years, caffeine has been generally believed to 
suppress cell proliferation, abolish cell cycle progression and enhance the toxicity 
of radiation and anticancer agents (Bode and Dong 2007). Specifically, caffeine 
has been reported to induce G1/S arrest and to reverse the G1/S and G2/M 
checkpoint delay periods. Importantly, when caffeine is combined with DNA-
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damaging agents, the potency of the DNA-damaging agent is increased 
markedly (Bode and Dong 2007). Many studies suggested that the increased 
toxicity of chemical agents is associated with caffeine’s inhibition of the G2 
checkpoint activity, which would accelerate movement of the cell cycle through 
the G2/M checkpoint, thus leaving cells less time to repair DNA damage and 
eventually lead them to apoptosis.  
 The cellular effects of caffeine resemble some defects observed in ataxia 
telangiectasia (AT) cells. Current studies support the evidence that ATM and 
ATR are primary targets of caffeine (Bode and Dong 2007). ATM and ATR 
belong to the phosphatidylinositol-3 kinase (PI-3 kinase) and caffeine has been 
shown to inhibit various forms of PI-3 kinase. Moreover, caffeine also target 
protein p53, a tumor suppressor protein that is believed to be the primary 
mediator of cell cycle arrest and induction of apoptosis in most cell lines in 
response to DNA damage. 
2.5 KU55933 and Its Molecular Mechanism 
 
 KU-55933 has recently been discovered and is found to have great 
selectivity for ATM that is 100-fold greater than other related kinases. Studies 
have shown that KU-55933 induces cell cycle arrest at the G1 phase and leads to 
apoptosis under serum starvation conditions (Li and Yang 2010).  
2.6 VE-821 and Its Molecular Mechanism 
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 VE-821 is a potent and competitive inhibitor of ATR. Inhibition of ATR led 
to inhibition of DNA-damage-induced G2/M arrest in cancer cells.  Treatment of 
cancer cells with anticancer agents along with VE-821 has shown to increase 
DNA damage and inhibit homologous recombination repair (Prevo et al 2012). 
This evidence suggests that ATR inhibition with VE-821 is a novel approach to 
cancer therapy.  VE-821 along with cisplatin treatment shows marked synergy 
(Prevo et al 2012).  
2.7 MG-132 and Its Molecular Mechanism 
 
 MG-132 is a proteasome inhibitor. It has been shown to inhibit cellular 
proliferation and induce cell death in esophageal squamous cell carcinoma 
(Crawford et al 2006).  MG-132 induces apoptosis through the activation of class 
III PI3K pathway and the release of caspase-3.   
2.8 UM-SCC-38 Cells 
 
 UM-SCC-38 cell line was obtained from Dr. Thomas E. Carey (University 
of Michigan, Ann  Arbor). The cells were originated from a tissue sample of a 60-
year-old patient with squamous cell carcinoma of the oropharynx. Previous study 
by Wang et al (2012) showed that among the UM-SCC cell lines, SCC-38 was 
most resistant to cisplatin. Therefore, we determine it would be most ideal to 
study the behavior of SCC-38 to cisplatin in adjunct with other agents/inhibitors.   
2.9 HaCaT Cells 
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 HaCaT cells are immortalized, non-tumorigenic human keratinocyte.  
HaCaT cells have been shown to be much more sensitive to cisplatin treatment 
compared to SCC-38 (Wang et al 2012). For this reason, we will use HaCaT cells 
as control for our experiment. 
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1 Cell culture 
 
The oral squamous cell carcinoma cell line, UM-SCC-38, was obtained 
from Dr. Thomas Carey (University of Michigan, Ann Arbor, MI.) and cells were 
grown in Dulbecco’s modified Eagle’s medium (DMEM, Sigma Chemical Co., St. 
Louis, MO.) supplemented with 10% fetal bovine serum (Hyclone Laboratories, 
Logan, UT).  They were incubated in a humidified atmosphere of 5% CO2 at 37-
oC.  HaCat cells were obtained from Dr. Pam Jensen (University of Pennsylvania, 
Philadelphia, PA.) and were passaged using DMEM medium lacking calcium 
(Invitrogen, Grand Island, NY.) supplemented with 10% fetal bovine serum.  
Unless specified, prior to each live cell microscopy cells were transferred to a 6-
well plate (CELLTREAT Scientific Products, Shirley, MA) and grown in DMEM 
medium for 24 hours prior to treating with appropriate drug or inhibitor 
concentrations. 
3.2 Cisplatin preparation 
 
 Cisplatin was purchased in powder form, cis-diammineplatinum (II) 
dichloride (Sigma, St. Louis, MO). Cisplatin has a molecular weight of 300.01 
g/mol. The stock solution was prepared in purified water (ddH2O) to 3 mM and 
kept in -20oC environment. A new bath of 3 mM stock solution was prepared 
every 6 months to avoid any potential long-term changes to the structures of the 
complex. Unless specified, cisplatin was used at a final concentration of 16 µM 
throughout this entire experiment.   
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3.3 Inhibitor preparation 
 
 The following inhibitors were used: caffeine (Sigma, St. Louis, MO), KU 
55933, an ATMi inhibitor (EMD Chemicals), VE-821, an ATRi inhibitor (SELLECK 
Chemical LLC) and Mg-132, a proteasome inhibitor (Sigma, St. Louis, MO). 
Caffeine (anhydrous) has a molecular weight of 194.2 g/mol. Caffeine stock 
solution was prepared in purified water (ddH2O) to 100 mM. KU 55933, VE-821 
and Mg-132 were all purchased in power form and dissolved in DMSO to make a 
stock solution of 5 mM, 10 mM and 100 mM, respectively.  All inhibitors were 
stored and kept in -20oC environment.  The final concentrations of these 
inhibitors were obtained from the literatures and they are 4 mM for caffeine, 20 
µM for KU-55933, 10 µM for VE-821, and 5 µM for Mg-132 (Ashley et al 2014).  
3.4 Pilot study design 
3.4.1 Determining the best cisplatin concentration 
 
 The purpose of the pilot study was to determine the best dose and 
timeframe to study cell death. Two days prior to live cell microscopy cells were 
passaged and seeded in a 24-well plate (CELLTREAT Scientific Products, 
Shirley, MA) at roughly 50 to 80% confluence. Each well contained 1 mL DMEM 
and the plate was incubated at 37oC for 24 hours.  On the next day cells were 
treated at four different cisplatin concentrations: 4 µM, 8 µM, 16 µM, and 32 µM 
(Fig. 3.4.1). The plate was incubated again for another 24 hours. The following 
observations were made after 24 hours: almost all cell death were observed in 32 
µM wells, minimal to no cell death at 4 µM wells and roughly 50% cell death 
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observed at 16 µM wells. Therefore, we decided 16 µM cisplatin would be the 
optimal cisplatin concentration to study cell death.  
3.4.2 Does caffeine alone have any effect on cell behavior? 
 
  To ensure that caffeine alone does not have significant effect on cell 
behavior, we performed a pilot study of caffeine treatment.  Similar to cisplatin 
setup above, UM-SCC-38 cells were seeded in a 6-well plate. It was incubated at 
37oC for 24 hours. On the second day, only caffeine (4 μM) was added to the 
experimental well (Figure 3.4.2). However, instead of tracking cell behavior under 
the time lapse microscope, we incubated the plate again for another 24 hours. 
The cells were observed under the light microscope and an image was taken to 
capture the post-caffeine cell population as well as the control group (Figure 
4.5.4). Clearly, caffeine alone did not show any significant effect on cell death 
compared to the control group. 
3.5 Time Lapse Experiment and Study Design  
3.5.1 Cisplatin Only  
 One day prior to time lapse microscopy, UM-SCC-38 cells were seeded in 
a 6-well plate at roughly 80% confluence. Each 35-mm well contained 2.5 mL 
DMEM solution. The plate was then incubated at 37oC for 24 hours. Twenty-four 
hours later, cisplatin was added to the experimental well. The control well was 
imaged without any drug to serve as control. The amount of drug was calculated 
based on the amount of solution in the well and the desired drug concentration. 
For example, 16 µM cisplatin in 2.5 mL solution is calculated as follow:  
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𝑎𝑚𝑡. 𝑜𝑓 𝑐𝑖𝑠𝑝𝑙𝑎𝑡𝑖𝑛 𝑛𝑒𝑒𝑑𝑒𝑑 (µ𝐿) =
16µ𝑚𝑜𝑙
𝐿
𝑥
2.5 𝑚𝑙
𝑥
𝐿
1000𝑚𝐿
𝑥
𝐿
300µ𝑚𝑜𝑙
𝑥
106
𝐿
= 133.3µ𝐿  
16µ𝑚𝑜𝑙
𝐿
    = 𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑐𝑖𝑠𝑝𝑙𝑎𝑡𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛  
2.5 𝑚𝑙       = 𝑣𝑜𝑙𝑢𝑚𝑒 𝑖𝑛 𝑒𝑎𝑐ℎ 𝑤𝑒𝑙𝑙  
𝐿
1000𝑚𝐿
    = 𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 𝑢𝑛𝑖𝑡  
𝐿
300µ𝑚𝑜𝑙
   = 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑖𝑠𝑝𝑙𝑎𝑡𝑖𝑛 𝑠𝑡𝑜𝑐𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛  
Unless specified, the amount of cisplatin remained constant through this entire 
experiment. The plate was then loaded into Zeiss time-lapse microscope for 24-
hour imaging. Figure 3.5.1 illustrates cisplatin study design.  
3.5.2 Cisplatin and MG-132  
 
 All procedures all similar as mentioned above. The design is illustrated in 
figure 3.5.2. The amount of MG-132 was calculated as follow: 
𝑎𝑚𝑡. 𝑜𝑓 𝑀𝐺132 𝑛𝑒𝑒𝑑𝑒𝑑 (µ𝐿) =
5µ𝑚𝑜𝑙
𝐿
𝑥
2.5 𝑚𝑙
𝑥
𝐿
1000𝑚𝐿
𝑥
𝐿
1000µ𝑚𝑜𝑙
𝑥
106
𝐿
= 12.5µ𝐿  
3.5.3 Cisplatin and Caffeine  
 
 The study design for cisplatin and caffeine is illustrated in figure 3.5.3. The 
amount of caffeine was calculated as follow: 
𝑎𝑚𝑡. 𝑜𝑓 𝑐𝑎𝑓𝑓𝑒𝑖𝑛𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 (µ𝐿) =
4𝑚𝑚𝑜𝑙
𝐿
𝑥
2.5 𝑚𝑙
𝑥
𝐿
1000𝑚𝐿
𝑥
𝐿
100𝑚𝑚𝑜𝑙
𝑥
106
𝐿
= 100µ𝐿  
3.5.4 Cisplatin and ATMi/ATRi 
 
 The study design for cisplatin and ATMi/ATRi is illustrated in figure 3.5.4. 
The amounts of KU-55933 and VE-821 are calculated as follow: 
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𝑎𝑚𝑡. 𝑜𝑓 𝐾𝑈 − 55933 𝑛𝑒𝑒𝑑𝑒𝑑 (µ𝐿) =
20µ𝑚𝑜𝑙
𝐿
𝑥
2.5 𝑚𝑙
𝑥
𝐿
500µ𝑚𝑜𝑙
𝑥
106µ𝐿
𝐿
= 100µ𝐿  
𝑎𝑚𝑡. 𝑜𝑓 𝑉𝐸 − 821 𝑛𝑒𝑒𝑑𝑒𝑑 (µ𝐿) =
10µ𝑚𝑜𝑙
𝐿
𝑥
2.5 𝑚𝑙
𝑥
𝐿
1000𝑚𝐿
𝑥
𝐿
100µ𝑚𝑜𝑙
𝑥
-106
𝐿
= 250µ𝐿  
 
3.5.5 Live cell microscopy and cell imaging analysis 
 
Immediately after drug/inhibitor addition, live cell imaging was performed 
using a Zeiss Microscope with Marianas Software (Intelligent Imaging 
Innovations, Inc. Denver, CO.), with images collected at 10X objective every 10 
minutes for 24 hours. Image sequences were viewed using Slidebook Reader 5.5 
(Intelligent Imaging Innovations, Inc. Denver, CO.). Once the live cell microscopy 
was completed, the captured images were loaded into SlideBook Reader 
Software (3i, Denver, CO). In each well one hundred cells were tracked for cell 
fates (Figure 3.5.5).   
3.6 Graphs Generation 
 
 Cell behaviors were recorded manually and entered into Microsoft Excel 
Spreadsheet to generate cell profile graphs (Figure 3.6).  
3.7 Statistical Analysis 
 
 Statistical significance was analyzed using an unpaired 2-tailed Student’s 
t-test. The values are presented as the means ± standard errors. A P-value <0.05 
was considered statistically significant.  
 
16 
 
              
Figure 3.3.1. Pilot study design 
SCC-38 cells were treated with 16 different combinations of cisplatin 
concentration and cellular confluence.  Each well contained 1 mL DMEM 
solution. Left column contained SCC-38 cells without cisplatin treatment to serve 
as control. 
 
       
Figure 3.3.2. Caffeine only study design 
SCC-38 cells were treated with or without 4 mM caffeine only.   
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Figure 3.5.1. Preparing for cisplatin time-lapse experiment 
SCC-38 cells were seeded in 6-well plate. They were treated with or without 16 
µM cisplatin.  
 
 
Figure 3.5.2. Preparing for cisplatin-Mg-132 time-lapse experiment 
SCC-38 cells were treated with cisplatin alone or cisplatin plus Mg-132 
combination.  
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Figure 3.5.3. Preparing for cisplatin-caffeine time-lapse experiment 
SCC-38 cells were treated with cisplatin alone or cisplatin plus caffeine 
combination  
 
                
Figure 3.5.4. Preparing for cisplatin-caffeine time-lapse experiment 
SCC-38 cells were treated with cisplatin alone, cisplatin-KU55933 or cisplatin-
VE-821 combination.  
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Figure 3.5.5.  SCC-38 cell labeling 
This image illustrates a time-lapse image with one hundred SCC-38 cells labeled. 
Each cell was tracked for their behavior during the entire 24-hour experiment.  
  
  
Figure 3.6. Recorded SCC-38 cell behavior 
This image provides an example of recorded cell behavior. The data were 
entered into Microsolf Excel to generate figure profiles.  
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CHAPTER 4: RESULTS 
 
4.1 Chemoresistant cancer cells display diverse fate profiles 
 
 As discussed in our literature review section, SCC-38 cell line was 
selected because this head and neck squamous cell carcinoma (HNSCC) has 
been previously characterized to be resistant to cisplatin treatment (Wang et al 
2012, Brenner  2010). To shed new light on cisplatin resistance, live cell imaging 
was utilized to determine the initial fate of UM-SCC38 cells after cisplatin 
exposure (Fig. 4.1.1, Fig. 4.1.2). Cell profiles from six consecutive experiments 
show consistent results: the vast majority of unperturbed SCC-38 cells 
underwent normal cell division, while a dramatically different cell fate profile 
existed in the presence of cisplatin (Fig. 4.1.3). As expected, a significant 
induction of cell death was observed in cells exposed to cisplatin, 60% compared 
to 15% cell death in untreated sample (Table 4.1). Cell death was further 
investigated for the cell cycle stage in which it occurred. For example, death in 
interphase defined those cells that died in the immediate interphase without 
mitotic entry; death in mitosis characterized those that entered mitosis and died 
during mitosis; and finally, some cells died in the second interphase after mitotic 
entry and exit. As evident in Figure 4.1.4, the majority of cell death (45%) 
induced by cisplatin occurred in interphase without mitotic entry. A moderate 
increase (13%) was documented in cell death in interphase after the first mitosis, 
but no increase was seen in the portion of mitotic cell death (Fig. 4.1.4). 
Therefore, although mitotic cell death has been implicated in chemotherapy, e.g. 
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via mitotic catastrophe, it did not appear to play a significant role in the treatment 
of cancer cells with cisplatin.  
Consistent with the previously characterized chemoresistance of SCC-38 cells, 
significant portions of cells (40%) survived the treatment. As shown in Figure 
4.1.5, cisplatin induced DNA damage checkpoint was evidenced by 
approximately 25% of cells remained in the interphase throughout the 24-hour 
period, compared to 2% in the drug-free group. The activation of DNA damage 
checkpoint after cisplatin treatment was consistent with previous study (Galluzzi 
et al 2011; Prendergast et al 2011; Pabla et al 2008). Moreover, an average 14% 
of cells underwent continuous cell cycle progression despite cisplatin treatment. 
Thus, this portion of cells escaped the induction of cell death and checkpoint 
arrest (Fig. 4.1.6). This cell fate choice is classified here as “checkpoint 
slippage”, as also implicated in previous studies (Shaltiel et al 2015, Bartek et al 
2007, Clemenson et al 2009, Syljuasen 2007). The nature of checkpoint slippage 
is not fully understood at the present moment. In principle, the deficiency of 
checkpoint activation can lead to continued cell division after DNA damage. 
Alternatively, the checkpoint may be initially activated but de-activated 
subsequently due to DNA repair, or hyperactivation of checkpoint recovery or 
adaptation mechanisms (Clemenson et al 2009, Syljuasen 2007, Peng 2013)  
Interestingly, cells in the group of checkpoint slippage entered mitosis in 
approximately 3.5 hours after cisplatin-treatment (Fig. 4.1.7). By comparison, 
mitotic entry in unperturbed cells took 7 hours in average (Fig. 4.1.7). We 
speculated that the difference in the timing of mitotic entry reflected a cell cycle-
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dependence of checkpoint slippage. For example, cells slipped into mitosis were 
exposed to cisplatin in late S and G2 phases, whereas cells treated in G1 and 
early S phases was effectively prevented from mitotic entry due to checkpoint 
arrest or cell death. There are several possible mechanisms underlying this 
observation. First, induction of DNA damage by cisplatin may be less efficient in 
late S and G2 cells, or alternatively, the DNA damage checkpoint in late S and 
G2 is inadequate in preventing mitotic entry. Notably, previous studies indicated 
that an imperfect G2/M DNA damage checkpoint failed to halt the cell cycle with 
a subthreshold level of DNA damage (Deckbar et al 2007; Krempler et al 2007). 
4.2 Duration of mitotic arrest does not dictate cell fate 
 
Mitotic arrest can result from erratic progression of mitosis and activation of the 
mitotic spindle checkpoint. Surprisingly, no mitotic arrest was induced by cisplatin 
treatment, as cells in the control and cisplatin-treated groups spent similar 
amount of time in mitosis, 43 minutes and 40 minutes, respectively (Fig. 4.2.1). 
We further separated the cisplatin-treated and mitotic-entering cells into three 
groups based on their subsequent cell fate: died in mitosis, exited mitosis and 
survived, or exited mitosis and died in the following interphase (Fig. 4.2.2). We 
observed no correlation between mitotic duration and the subsequent cell fate 
after mitotic exit (Fig. 4.2.2). Therefore, we concluded mitotic duration does not 
predict cell death or survival in the subsequent interphase. However, dramatically 
prolonged mitosis was associated with mitotic death, as cells that destined to die 
in mitosis spent an average of 126 minutes in mitosis before undergoing 
apoptosis (Fig. 4.2.2). This finding suggested delaying mitotic exit may enhance 
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the effectiveness of cisplatin by inducing cell death in mitosis. To directly test this 
hypothesis, we co-treated SCC-38 cells with Mg-132, a proteasome inhibitor 
known to suppress M-phase exit (Skoufias et al 2007).  Very surprisingly, the 
combination of cisplatin and Mg-132 caused 96% mitotic cell death, compared to 
less than 4% with cisplatin alone (Fig. 4.2.3). Similarly, the finding was confirmed 
in Dr. Peng’s lab with cell proliferation and clonogenic assays (Fig. 4.2.4, Fig. 
4.2.5). 
4.3 SCC-38 M-phase cells are hypersensitive to cisplatin 
 
As we understood, cisplatin induced cell death by causing DNA crosslinking, the 
process that interferes with DNA replication and transcription (Galluzzi et al 2011; 
Caponigro et al 2006). Moreover, recent studies revealed that mitotic DNA 
damage responded differently from that of interphase cells; it is often diminished 
(Heijink et al 2013; Giunta et al 2010). Hence, this knowledge prompted us to 
examine the fate of cells exposed to cisplatin during mitosis, a cell cycle stage in 
which DNA replication and transcription are suppressed. Figure 4.3.1 represents 
a collection of M-phase cells that were exposed to cisplatin from all of our 
experiments.  Similar to interphase cells, M-phase cells exhibited multiple fates 
following cisplatin exposure (Fig. 4.3.1).  However, M-phase cells were extremely 
sensitive to cisplatin, and the chance of cell survival was markedly reduced in 
cells exposed to cisplatin in mitosis: 7% survival in M-phase compared to 44% in 
interphase (Fig. 4.3.2). Of the 93% of M-phase cells died after cisplatin 
treatment, 34% died during mitosis and the other 59% completed cell division, 
and then died in the subsequent interphase (Table 4.3). Furthermore, 29% of 
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cells died in early mitosis prior to any sign of cell division, whereas 5% cells 
death occurred in late stages of mitosis. In light of these results, we concluded 
that 1) cisplatin exerted cytotoxicity in mitotic cells independent of DNA 
replication and transcription, and 2) cisplatin induced cell death in mitotic cells 
with a much higher potency compared to that in interphase cells.  
4.4 Chemoresistant cells are protected from cell death by both checkpoint 
arrest and slippage 
 
To better understand the cisplatin resistance of SCC-38 cells, we comparatively 
analyzed the cell fate profile of HaCaT, a spontaneously transformed 
keratinocyte cell line known to be cisplatin-sensitive (Wang et al 2012).  Cell 
profiles of SCC-38 and HaCaT being treated with cisplatin are shown in Figure 
4.4.1. Evidently, marked difference in cell fate profiles was noticed between 
cisplatin-treated SCC-38 and HaCaT cells. As expected, cisplatin induced cell 
death more efficiently in HaCaT cells (Fig. 4.4.1). Approximately 88% of HaCaT 
cells died in interphase compared to 45% of SCC-38 cells (Fig. 4.4.2). By 
comparison, cell death in mitosis or cell death in interphase after the first mitosis 
was not increased, but rather moderately reduced in HaCaT cells (Fig. 4.4.2). 
Importantly, and in sharp contrast to SCC-38 cells, HaCaT cells exhibited much 
less checkpoint activation and checkpoint slippage in response to cisplatin.  Only 
4% HaCaT cells remained arrested in interphase in comparison to 28% in SCC-
38; and 1% of HaCaT cells underwent continued cell cycle progression in the 
presence of cisplatin, compared to 11% of SCC-38 cells (Fig. 4.4.3). This 
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comparative study of cell fate profiles underlied the critical role of both checkpoint 
activation and slippage in protecting cells from cell death, which may 
subsequently lead to cancer resistance. 
4.5 Caffeine sensitizes cell death by abolishing both checkpoint activation 
and checkpoint slippage 
 
It has been suggested that targeting the cellular DDR mechanism rendered cell 
defenseless.  We thought this process would make cancer cells more susceptible 
to radiation and chemotherapy. For example, it is typically thought that disruption 
of the DNA damage checkpoint will allow cell cycle progression after DNA 
damage. And subsequently, cell division with unrepaired DNA damage leads to 
further accumulation of DNA damage, mitotic defects, and eventually, cell death. 
Our objective was to determine how the checkpoint disruption would affect the 
determination of cell fate choices in SCC-38 cells treated with cisplatin. First, it 
was confirmed, with Western blot in Dr. Aimin Peng’s lab, that caffeine, a well-
characterized inhibitor of ATM and ATR, effectively silenced DNA damage 
checkpoint signaling induced by cisplatin in SCC-38 cells, as evidenced by 
impaired phosphorylation of Chk1 and Chk2 (Fig. 4.5.1). We then performed four 
consecutive time lapse imaging experiments with caffeine and cisplatin treatment 
and cell profile data show consistent results (Figure 4.5.2). Caffeine plus cisplatin 
treatment resulted in 88% cell death in interphase, significantly higher than 51% 
observed in cisplatin only treatment (P<0.001,Figure 4.5.3). However, no 
significant cell death in mitosis or the second interphase following the first mitosis 
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was observed between the cisplatin only and cisplatin-caffeine treatments (Fig. 
4.5.3). This effect of caffeine strongly argued that checkpoint disruption directly 
sensitizes cell death without either mitotic entry or accumulation of DNA damage 
due to mitotic defects. To determine how much effect caffeine had on cell 
behavior alone and to serve as a control, we conducted a pilot study in which 
SCC-38 cells were treated with the same concentration caffeine (4 mM). As 
indicated in Figure 4.5.4, caffeine did not induce cell death in SCC-38 cells. We 
then compared the portions of surviving cells between groups of cisplatin alone 
and cisplatin/caffeine combination treatment. As expected, caffeine abolished the 
portion of interphase arrested cells (Fig. 4.5.5), presumably by suppressing the 
ATM/ATR-mediated DNA damage checkpoint. To our surprise, caffeine 
treatment also completely eliminated the portion of checkpoint slippage, as 
essentially no cell was able to successfully complete cell division in the presence 
of caffeine and cisplatin (Fig. 4.5.5). Collectively, caffeine treated SCC-38 
responded to cisplatin in a manner similar to the chemosensitive HaCaT cell. 
Again, our findings with live cell microscopy were confirmed in Dr. Peng’s lab that 
caffeine greatly enhanced the efficacy of cisplatin in SCC-38 cells using both cell 
proliferation and clonogenic assays (Fig. 4.5.6, Fig. 4.5.7). 
4.6 Inhibition of ATR, but not ATM, sensitizes interphase cell death 
 
Caffeine inhibits both ATM and ATR, the two upstream DDR kinases. It has been 
well illustrated that ATM and ATR, though sharing great similarity in structural 
elements and substrate recognition, respond to different types of DNA lesions 
and are activated by distinct mechanisms (Shiloh 2003). To better understand 
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the involvement of ATM and ATR in DNA repair mechanism, we utilized specific 
inhibitors that selectively target either ATM or ATR. As discussed and confirmed 
previously in Dr. Peng’s lab with Western blot, KU-55933 (ATMi) inhibited 
phosphorylation of Chk2 in response to cisplatin, whereas VE-821 (ATRi) 
disrupted ATR-dependent phosphorylation of Chk1 (Fig. 4.5.1).  
Based on the cell profile data from four consecutive time-lapse microscopy 
experiments, the results were very consistent (Fig. 4.6.1). ATM inhibition did not 
significantly alter the profile of cell fate choices after cisplatin treatment (Fig. 
4.6.2). For instance, on average 50% of SCC-38 cells treated with cisplatin 
resulted in cell death in interphase without mitotic entry, while 45% of SCC-38 
cells experienced similar fate when exposed to cisplatin-ATMi combination 
(P>0.05).  Moreover, 11.8% of SCC-38 cells treated with cisplatin died in the 
second interphase following the first mitosis, compared to 11.5% of cancer cells 
underwent similar fate in cisplatin/ATMi combination group (P>0.05). Only a 
moderate induction of mitotic cell death was detected with ATM inhibition 
(P=0.03, Fig. 4.6.2). In addition, we observed no difference between cisplatin 
only and cisplatin/ATMi treated cells in term of cell survival via interphase arrest 
(checkpoint activation) or checkpoint slippage (Fig. 4.6.3). ATR, on the other 
hand, sensitized interphase cell death to approximately 70%, as compared to 
50% in the group of cisplatin-treated only group(P=0.03, Fig. 4.6.2). Moreover, 
ATR inhibition substantially reduced the number of cells that were arrested in 
interphase or underwent checkpoint slippage (Fig. 4.6.3). The impact of ATR 
inhibition on the profile of post-cisplatin cell fate resembled that of caffeine, 
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suggesting that ATR, rather than ATM, plays a major role in cell fate 
determination after cisplatin treatment. Our conclusion was later confirmed by the 
works in Dr. Peng’s lab using cell proliferation and clonogenic assays (Fig. 4.6.4, 
Fig. 4.6.5). Thus, ATR-mediated checkpoint pathway presents a promising target 
to improve the therapeutic outcome using cisplatin.   
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Figure 4.1.1. Time-lapse sequences of SCC-38 cell  
This figure illustrates the time-lapse sequences illustrating the fates 
exhibited by SCC-38 cells following prolonged exposure to cisplatin, 16 
µM.  
The four main behaviors of SCC-38 cells observed using time-lapse 
microscope were proliferation in interphase, division, death in mitosis and 
death in interphase. 
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Figure 4.1.2. Profiling the cell fate choices 
This figure illustrates how cell profile was constructed. Each horizontal line 
represents one cell, with the length of the line corresponding to the duration of a 
given behavior. The color of the line represents cell behavior. 
Note, when cells exit mitosis and remain in the interphase for the remainder of 
the experiment, the line ends when the cell exits mitosis. 
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Figure 4.1.3. Diverse cell fate choices in resistant cancer cells treated 
with cisplatin 
As described in Methods and Materials, cell fate profiles of SCC-38 cells 
treated with or without cisplatin were quantified. A representative 
experiment is shown. 
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Cell Behavior Distribution 
Cell behavior Control (%) Cisplatin (%) 
a: No mitotic entry 2.4 25.4 
b: Death in interphase 5.4 45.4 
c: Entering mitosis and dividing 70.4 13.8 
d: Entering mitosis, dividing, death in interphase 6.0 13.0 
e: Entering mitosis and death in mitosis 3.6 1.2 
 
Table 4.1. Cell behavior distribution  
Table showing the percentage of SCC-38 cells in each behavioral category in the control 
and cisplatin treated samples. Please note: there are small percentage of cells 
underwent different cell fate and are not included in this table.   
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Figure 4.1.4. The induction of cell death by cisplatin in UM-SCC38 cells 
The percentages of cells underwent interphase cell death without mitotic entry, 
death in mitosis, or in the subsequent interphase following the first mitosis were 
shown. SCC-38 cells without cisplatin treatment were included as a control. 
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Figure 4.1.5. Cell cycle arrest in interphase  
The percentages of cells that were arrested in interphase were shown in UM-
SCC-38 cells with or without cisplatin. 
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Figure 4.1.6.  Continuous cell proliferation  
The percentages of cell that exhibited continued cell proliferation (as judged by 
mitotic entry) were shown in SCC-38 cells with or without cisplatin.  
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Figure 4.1.7. Time before mitotic entry 
The length of interphase prior to mitotic entry was shown in the control and 
cisplatin-treated SCC-38 cells.  
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Figure 4.2.1. Mitotic duration of SCC-38 cells 
The average amount of time, in minutes, that SCC-38 cells spent in mitosis when 
treated with or without cisplatin is shown.  
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Figure 4.2.2. Mitotic duration of three post-mitotic cellular behaviors 
The duration of mitotic arrest, in minutes, of three different behavioral groups of 
SCC-38 cells is shown. 
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Figure 4.2.3. Cell fate choices of SCC-38 cells  
Cell fate profiles of HNSCC-38 cells when treated with a combination of 16 µM 
cisplatin and 5 µM Mg-132 
 
  
0 500 1000
f
e
d
c
b
a
SCC-38/Control 
Time (min) 
0 500 1000
e
D
'
b
Cisp/MG-132 
Time (min) 
40 
 
 
 
 
 
 
 
 
Figure 4.2.4. SCC-38 cell proliferation under the influence of drug and/or 
inhibitor 
The SCC-38 cells were divided into three groups and subjected to cisplatin only, 
Mg-132 only, or cisplatin plus Mg-132 over a period of 4 days. The cell 
proliferation in each group was measured after each day, using hemocytometer, 
and the plot shows the proliferation of cells over a 4-day period. The relative cell 
number compared to the actual starting number on day 1 is shown.  
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Figure 4.2.5. Cologenic assay 
SCC-38 cells were untreated (control), treated with cisplatin only, Mg-132 only, or 
cisplatin combined with Mg-132.  
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Figure 4.3.1. SCC-38 M-phase cell profile 
Cell fate profiles of HNSCC-38 cells in M-phase when treated with or without 
cisplatin quantified and shown. 
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Figure 4.3.2. Asynchronized and M-phase SCC-38 cell survival 
The percentages of cell survival in interphase or M-phase SCC-38 cells when 
treated with cisplatin.  
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M-phase Cell Behavior Responding to Cisplatin Treatment 
Cell Behaviors % 
f: Dividing during mitotic phase 7 
g: Dividing and death in interphase 59 
G’: Dividing and death in mitosis 5 
h: Interphase between mitosis 0 
I: Death in mitosis 29 
 
Table 4.3.  M-phase cell behavior responding to cisplatin treatment 
Table shows the distributions cell death of SCC-38 cells responding to cisplatin during 
M-phase.  
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Figure 4.4.1. Cell fate profiles of HaCaT cells 
Cell fate profiles of HaCaT cells treated with or without cisplatin quantified and 
shown. A representative experiment is shown.   
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Figure 4.4.2. The induction of cell death by cisplatin in SCC-38 and HaCaT 
cells  
The percentages of cells underwent interphase cell death without mitotic entry, 
death in mitosis, or in the subsequent interphase following the first mitosis were 
compared and shown between these two cell lines.  
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Figure 4.4.3. Cell survival via either checkpoint activation or checkpoint 
slippage 
The percentages of HaCaT and SCC-38 cells that survived cisplatin treatment by 
checkpoint activation and checkpoint slippage are shown.  
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Figure 4.5.1. Western blotting 
SCC-38 cells were treated with cisplatin, caffeine, and specific inhibitors of ATM 
and ATR (ATMi and ATRi). Phosphorylation of Chk1 and Chk2, and total Chk2 
are shown by immunoblotting.  
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Figure 4.5.2. Cell fate choices of SCC-38 cells  
Cell fate profiles of SCC-38 cells treated with cisplatin or cisplatin-caffeine 
combination. The concentrations for cisplatin and Mg-132 were 16µM and 5µM, 
respectively. A representative experiment is shown. 
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Figure 4.5.3. The induction of cell death by cisplatin plus caffeine in SCC-38 
cells  
The percentages of SCC-38 cells underwent interphase cell death without mitotic 
entry, death in mitosis, or in the subsequent interphase following the first mitosis 
were shown. SCC-38 cells without caffeine treatment (cisplatin only) were 
included to serve as comparison.  
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Figure 4.5.4. Light microscope photographs of SCC-38 cells 
Images were taken of SCC-38 cells under the light microscope with or without 
caffeine treatment.  
As discussed in our paper, SCC-38 cells were treated with caffeine alone to 
determine if caffeine had any significant behavior on cancer cells. 
As evident, cell death was not significant between the two groups to warrant a 
time-lapse analysis.  
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Figure 4.5.5. Cell survival via checkpoint activation or checkpoint slippage 
The percentages of SCC-38 cells that survived the cisplatin plus caffeine 
treatment by checkpoint activation and checkpoint slippage were shown. SCC-38 
cells with cisplatin only treatment were included as comparison.  
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Figure 4.5.6. Cell proliferation 
The SCC-38 cells were divided into three groups and subjected to cisplatin only, 
caffeine only, or cisplatin plus caffeine over a period of 4 days.The cell 
proliferation in each group was measured after each day, using hemocytometer, 
and the plot shows the proliferation of each group of cells over a 4-day period.  
The relative cell number compared to the actual starting number on day 1 is 
shown. 
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Figure 4.5.7. Clonogenic assay 
SCC-38 cells were untreated (control), treated with cisplatin only, caffeine only, 
or cisplatin combined with caffeine.  
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Figure 4.6.1. Inhibition of ATR, but not ATM, sensitizes the cisplatin 
treatment 
SCC-38 cells were treated with cisplatin and ATM/ATR inhibitors as indicated. A 
representative experiment is shown.   
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Figure 4.6.2. The induction of cell death by cisplatin and ATM/ATR 
inhibitors in SCC-38 cells 
The percentages of cells underwent interphase cell death without mitotic entry, 
death in mitosis, or in the subsequent interphase following the first mitosis were 
shown.  
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Figure 4.6.3. Cell survival via checkpoint activation or checkpoint slippage 
The percentages of SCC-38 cells that survived cisplatin and ATM/ATR inhibitors 
by checkpoint activation and checkpoint slippage.  
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Figure 4.6.4. Cell proliferation 
The SCC-38 cells were divided into three groups and subjected to cisplatin only, 
ATRi only, or cisplatin plus ATRi over a period of 4 days.The cell proliferation in 
each group was measured after each day, using hemocytometer, and the plot 
shows the proliferation of each group of cells over a 4-day period. The relative 
cell number compared to the actual starting number on day 1 is shown.  
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Figure 4.6.5. Clonogenic assay 
SCC-38 cells were untreated (control), treated with cisplatin only, ATR inhibitor 
only, or cisplatin combined with ATR inhibitor.  
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CHAPTER 5: DISCUSSION 
 
The ability to quantitatively measure individual cell death with live-cell imaging 
can reveal detailed information with respect to how cell fate choices are 
determined. In turn, the knowledge about cell fate choices will help us 
understand cancer resistance and improve treatment efficacy. In this study we 
profiled SCC-38 cell behavior in responding to cisplatin treatment. SCC-38 cell 
line was chosen due to its well-documented chemoresistance. Not surprisingly, a 
significantly smaller portion of SCC-38 cells died after the treatment when 
compared to HaCaT, a non-tumorigenic keratinocyte cell line. Interestingly, in 
both SCC-38 and HaCaT lines, the majority of cell death occurred in interphase 
without mitotic entry. By comparison, only small portions of cells either entered 
and then died in mitosis, or completed cell division and then died in the 
subsequent interphase. Analysis of the surviving SCC-38 cells revealed the co-
existence of checkpoint arrest and checkpoint slippage—some surviving cells 
remained arrested in interphase without mitotic entry, while another group of cells 
underwent active cell division without detectable delay in either interphase or M-
phase. Hence, our study revealed a complex pattern of cell fate choices in 
cancer cells treated with cisplatin.  
Furthermore, we examined the length of mitosis in cells that entered mitosis after 
cisplatin treatment. To our surprise, cisplatin treatment did not cause prolonged 
mitosis, indicating the absence of vital mitotic defects or activation of the mitotic 
spindle checkpoint. In principle, cells entered mitosis after therapeutic treatment 
may die in mitosis, die after mitotic exit, or complete mitosis and survive. As 
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reported in this study, all these choices existed in cisplatin-treated SCC-38 cells. 
We then further investigated if the duration of mitosis would predict cell death or 
survival in the subsequent interphase. However, no significant difference was 
observed in the length of mitosis regardless of the cell fate after mitotic exit; as 
post-mitotic cell death and survival groups spent 40 and 39 minutes, respectively, 
in mitotic phase. Very interestingly, we found that the small portion of cisplatin-
treated cells entered, and then died in mitosis typically spent more than 2 hours 
in mitosis prior to cell death. This association between the prolonged mitotic 
progression and mitotic cell death prompted us to examine the effect of delaying 
mitotic exit. We showed a surprisingly strong synergy between cisplatin and Mg-
132, a proteasome inhibitor that was known to suppress mitotic exit. Thus, our 
study suggested a promising strategy of combinatorial therapy using cisplatin 
and Mg-132, which shall be further evaluated in laboratory or clinical studies. 
Similar to interphase cells, SCC-38 cells exposed to cisplatin during mitosis 
exhibited diverse cell fates. However, the pattern of cell fate choices differed 
remarkably. Collectively, mitotic cells were more sensitive to cisplatin, and the 
majority of these cells died in mitosis or after mitotic exit. Thus, in addition to 
blocking DNA replication and transcription, our findings suggested cisplatin-
induced DNA damage also interfered with mitotic progression. Moreover, recent 
studies showed that the molecular pathways of DNA repair and DNA damage 
checkpoint are largely silenced during mitosis (Heijink et al 2013; Giunta et al 
2010). It has been also suggested that the mitotic suppression of DNA repair is 
beneficial as mitotic DNA repair may lead to chromosomal instability, e.g., via 
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telomere fusion (Orthwein et al 2014). Therefore, the hypersensitivity to DNA 
damage is a desirable choice for mitotic cells that lack the capability of DNA 
repair.   
Since DDR plays a key role in cell fate determination after DNA damage, it has 
been proposed that targeting the DDR may offer a powerful tool to overcome 
chemoresistance. In supporting of this notion, we found that SCC-38 cells treated 
with caffeine, an inhibitor of ATM and ATR, exhibited greatly enhanced cell death 
during cisplatin treatment. Contrary to the common assumption that checkpoint 
disruption would lead to cell death by allowing mitotic entry with DNA damage, 
our study showed that caffeine-cisplatin treatment almost exclusively induced cell 
death in interphase without mitotic entry. As expected, caffeine suppressed 
checkpoint activation after cisplatin treatment, and abolished the portion of cell 
survival via interphase arrest. Moreover, and perhaps counterintuitively, caffeine 
treatment also eliminated the portion of checkpoint slippage. Therefore, we 
speculate that caffeine may prevent checkpoint slippage at least partially by 
suppressing DNA repair, as supported by several recent studies (Zelensky et al 
2013; Tsabar et al 2015; Sabisz and Skladanowski 2008) 
In addition to inhibit ATM and ATR simultaneously using caffeine, we further 
advanced the study using inhibitors that specifically target either one of these 
kinases. Similar to caffeine, ATR inhibition reduced cell survival by preventing 
checkpoint arrest and checkpoint slippage, and enhancing cell death in 
interphase. By comparison, ATM inhibition exhibited no significant effect on cell 
death or survival. Therefore, the effect of caffeine in sensitizing the cisplatin 
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treatment is largely conferred through ATR inhibition. However, it should be 
noted that the effect of ATR inhibition appeared less profound compared to that 
of caffeine, which implies additional targets of caffeine, as suggested previously 
(Cortez 2003). 
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CHAPTER 6: CONCLUSION 
 
The diverse cell fate choices of SCC-38 and HaCaT cells were confirmed 
using live cell imaging. Our results showed the majority of cell death occurred in 
interphase without mitotic entry and a significantly smaller portion of SCC-38 
cells died after the cisplatin treatment when compared to HaCaT. On the other 
hand, analysis of the surviving SCC-38 cells revealed the co-existence of 
checkpoint arrest and checkpoint slippage.  However, caffeine was shown to 
abolish these surviving mechanisms in cisplatin treated cells since essentially no 
cells were able to survive cisplatin/caffeine treatment.  Moreover, our 
combination therapy of cisplatin plus MG-132 showed strong synergistic effect on 
SCC-38 cell death. And, inhibition of ATR, instead of ATM, may be a more 
promising pathway to improve therapeutic outcome of cisplatin treatment. 
Overall, our study revealed new insights into chemoresistance and suggested 
combinatorial strategies that potentially overcome cancer resistance.   
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